Carlos Eduardo Estrada De La Rosa | Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by World Top Scientists

Dr. Carlos Eduardo Estrada De La Rosa | Toxicology and Pharmaceutical Science | Research Excellence Award

Profesor | Instituto Jalisciense de Alivio al Dolor y Cuidados Paliativos | Mexico

Dr Carlos Eduardo Estrada De La Rosa is a senior pharmaceutical and public health researcher serving as Head of Pharmaceutical Services and Pharmacovigilance and Professor-Researcher at the Instituto Jalisciense de Alivio al Dolor y Cuidados Paliativos, with expertise in pharmacovigilance, hospital pharmacy, medication safety, pain management, and palliative care. He holds advanced training in pharmaceutical sciences, quality assurance, healthcare administration, public health, and doctoral-level specialization in health systems, complemented by international clinical and hospital practice experience. His professional career spans leadership roles in public health institutions, hospitals, and the pharmaceutical industry, where he has led quality systems, medication safety programs, and pharmacovigilance strategies. His research focuses on safe and rational medication use, optimization of pharmacotherapy in palliative care, opioid stewardship, patient safety models, and emerging therapeutic guidelines, with sustained contributions through national and international scientific presentations and applied clinical research. He has received multiple recognitions for advancing patient safety, served on expert panels, contributed to national therapeutic guidelines, and holds leadership memberships in prominent professional and scientific organizations.


View ORCID Profile


Featured Publications

 

Nceba Gqaleni | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by World Top Scientists

Prof. Nceba Gqaleni | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Research Professor at University of KwaZulu-Natal, South Africa

Professor Nceba Gqaleni is a renowned academic and researcher at the University of KwaZulu-Natal, South Africa. He currently serves as an Acting Academic Leader in the Discipline of Traditional Medicine and as a Research Professor. With a passion for integrating traditional medicine into mainstream healthcare, his research aims to address health challenges facing Africa, including HIV, diabetes, and cancer. His work on herbal treatments and immunomodulators has positioned him as a pioneer in exploring alternative therapies. Prof. Gqaleni’s research is characterized by the synergy between modern science and indigenous knowledge systems, contributing significantly to the global healthcare landscape. His work continues to impact public health, with ongoing clinical trials and innovative studies aimed at improving health outcomes. Additionally, he is committed to training the next generation of researchers, having mentored numerous postdoctoral, PhD, and master’s students.

Professional Profile

Education

Professor Nceba Gqaleni’s educational background is rooted in biochemistry, with a PhD in Biochemistry from the University of Strathclyde in Glasgow, UK. He also holds a Master’s degree in Biochemistry from the University of KwaZulu-Natal (UKZN), South Africa. His academic journey has been marked by a deep interest in both the molecular and traditional aspects of medicine, leading him to pursue research that bridges these fields. His formal education laid the foundation for a distinguished career in both academia and research, where he has applied his scientific expertise to explore alternative therapies and the integration of traditional medicine into contemporary health systems. Prof. Gqaleni’s educational path reflects a commitment to advancing knowledge and improving healthcare, particularly in the African context.

Professional Experience

Professor Gqaleni’s professional experience spans academia, research, and leadership. He currently holds the position of Acting Academic Leader in the Discipline of Traditional Medicine at the University of KwaZulu-Natal. His role involves guiding academic initiatives and research in traditional medicine, while also providing leadership in curriculum development and research supervision. In addition to his academic responsibilities, Prof. Gqaleni has led numerous significant research projects, particularly focused on traditional medicine’s role in addressing major health issues such as HIV and diabetes. His extensive work in supervising postgraduate students, including over 7 postdoctoral researchers, 12 PhD candidates, and 25 master’s students, demonstrates his dedication to nurturing the next generation of scholars and researchers. Prof. Gqaleni’s professional experience is a blend of academic excellence, mentorship, and groundbreaking research in the field of traditional medicine and biochemistry.

Research Interests

Professor Nceba Gqaleni’s research interests lie at the intersection of biochemistry and traditional medicine, with a primary focus on finding alternative treatments for diseases prevalent in Africa, such as HIV, diabetes, and cancer. He has led pioneering research on herbal compositions for the treatment of HIV and is currently conducting clinical trials for a patented HIV cure. In addition to HIV, his research extends to cancer therapies, immunomodulators, and the application of Indigenous phytotherapy in managing diseases like diabetes and HIV. Prof. Gqaleni’s ongoing research projects also explore the health and wellness of Indigenous peoples, particularly in the context of climate change and global health disparities. His work is driven by the goal of bridging the gap between traditional healing practices and modern medical approaches, thereby improving health outcomes in African communities and globally.

Awards and Honors

Professor Nceba Gqaleni’s career has been marked by significant achievements and recognition. He has been honored for his pioneering work in traditional medicine and biochemistry, particularly in the field of HIV and diabetes treatment. One of his notable accomplishments is the filing of a patent for a herbal composition aimed at curing HIV, which is currently undergoing clinical trials. Prof. Gqaleni has also received substantial funding for his research, including a $4.4 million NIH grant for a study on Indigenous phytotherapy. His contributions to science and public health have earned him the respect of both academic and medical communities. Prof. Gqaleni’s work in advancing the integration of traditional medicine into global health systems continues to garner international attention and recognition. His awards and honors reflect his exceptional leadership and groundbreaking contributions to healthcare research.

Conclusion

Professor Nceba Gqaleni demonstrates exceptional potential for the Best Researcher Award due to his innovative contributions to HIV treatment, integration of traditional medicine, and impactful mentorship. His work addresses critical health challenges in Africa, blending traditional knowledge with modern scientific methods. While broader dissemination and commercialization efforts could strengthen his profile, his contributions make him a strong contender for the award.

Publications Top Noted

  • Indigenous Medicinal Plants Used in the Management of Diabetes in Africa: 5 Years (2019–2024) in Perspective
    • Authors: Frimpong, E.K., Thembane, N., Hlatshwayo, S., Ngcobo, M., Gqaleni, N.
    • Year: 2024
    • Citations: 2
  • Review on the Anti-Hyperglycemic Potential of Psidium guajava and Seriphium plumosum L.
    • Authors: Thembane, N., Hlatshwayo, S., Ngcobo, M., Ngubane, P., Gqaleni, N.
    • Year: 2024
    • Citations: 1
  • Erratum: An in vitro study to elucidate the effects of Product Nkabinde on immune response in peripheral blood mononuclear cells of healthy donors
    • Authors: Setlhare, B., Letsoalo, M., Nkabinde, S.A., Ngcobo, M., Gqaleni, N.
    • Year: 2024
    • Citations: 0
  • An in vitro study to elucidate the effects of product Nkabinde on immune response in peripheral blood mononuclear cells of healthy donors
    • Authors: Setlhare, B., Letsoalo, M., Nkabinde, S.A., Ngcobo, M., Gqaleni, N.
    • Year: 2024
    • Citations: 1
  • Analysis of Three Species of Cassipourea Traditionally Used for Hypermelanosis in Selected Provinces in South Africa
    • Authors: Mpofana, N., Yalo, M., Gqaleni, N., Dlova, N.C., Hussein, A.A.
    • Year: 2024
    • Citations: 0
  • Melasma in People with Darker Skin Types: A Scoping Review Protocol on Prevalence, Treatment Options for Melasma, and Impact on Quality of Life
    • Authors: Mpofana, N., Chibi, B., Gqaleni, N., Kgarosi, K., Dlova, N.C.
    • Year: 2023
    • Citations: 3
  • The Effect of Melasma on the Quality of Life in People with Darker Skin Types Living in Durban, South Africa
    • Authors: Mpofana, N., Paulse, M., Gqaleni, N., Hussein, A., Dlova, N.C.
    • Year: 2023
    • Citations: 0
  • The Met and Unmet Health Needs for HIV, Hypertension, and Diabetes in Rural KwaZulu-Natal, South Africa: Analysis of a Cross-Sectional Multimorbidity Survey
    • Authors: Singh, U., Olivier, S., Cuadros, D., Ramnanan, A., Harilall, S., Gqaleni, N.
    • Year: 2023
    • Citations: 5
  • An Investigation into the Acute and Subacute Toxicity of Extracts of Cassipourea flanaganii Stem Bark In Vivo
    • Authors: Mpofana, N., Chipangura, J.K., Paulse, M., Hussein, A.A., Crouch, N.R.
    • Year: 2023
    • Citations: 2
  • Treatment of Melasma on Darker Skin Types: A Scoping Review
    • Authors: Mpofana, N., Chibi, B., Visser, T., Hussein, A.A., Dlova, N.C.
    • Year: 2023
    • Citations: 4

 

Yan Ni | Pharmaceutical Research | Best Researcher Award

Published on by World Top Scientists

Dr. Yan Ni | Pharmaceutical Research | Best Researcher Award

Executive Director, Passage bio, United States

Profile

Google Scholar

Researcher Evaluation for “Best Researcher Award”

Strengths for the Award:

Extensive Expertise in Drug Development: Yan G. Ni, PhD, has over 15 years of experience in drug development, particularly in small molecules, biologics, and gene therapies. His work spans several critical therapeutic areas, including neurological and cardiovascular diseases, immune-oncology, hematology, and rare diseases. His contributions to IND/CTA submissions and regulatory interactions further highlight his deep involvement in the field.

Leadership in Translational Biomarker and Precision Medicine: Dr. Ni has demonstrated significant expertise in integrating preclinical and clinical biomarker strategies, contributing to the successful design and execution of biomarker-based clinical endpoints. His role in implementing PK and immunogenicity strategies across different phases of studies showcases his ability to bridge the gap between research and clinical application, a crucial factor in modern drug development.

Proven Management Skills: Dr. Ni’s management experience is evident in his ability to build and lead high-performing cross-functional teams. His leadership roles in international professional organizations like the AAPS and SAPA, as well as his track record of mentoring and inspiring others, underline his effectiveness as a leader in both scientific and organizational contexts.

High Scientific Productivity: With over 35 peer-reviewed publications, several book chapters, and six U.S. patents, Dr. Ni’s scientific output is substantial. His contributions to industry white papers and his role as an organizer and invited speaker at national and international conferences further affirm his thought leadership in the field.

Recognition and Awards: Dr. Ni has received numerous prestigious awards, such as the Passage Bio High Impact Award, Regeneron High Impact Award, AAPS Excellence in Ligand Binding Assays Award, and Merck Award of Excellence. These accolades reflect his high-impact contributions to the field and recognition by peers and industry leaders.

Areas for Improvement:

Broader Impact Beyond Specialized Fields: While Dr. Ni’s expertise is well-recognized within specialized areas such as biomarkers, precision medicine, and drug development, expanding his influence into broader, interdisciplinary research domains could enhance his candidacy for a “Best Researcher Award.” For example, engaging in research that impacts public health or other critical global issues might increase his visibility and impact.

Further Innovation in Emerging Therapeutic Areas: While Dr. Ni has made significant contributions to established therapeutic areas, greater involvement in cutting-edge fields such as artificial intelligence in drug discovery or personalized medicine could position him as a pioneer in these rapidly evolving areas.

Enhanced Collaboration with Global Initiatives: Although Dr. Ni has demonstrated leadership in professional organizations and consortia, expanding his collaborative efforts to include global health initiatives or large-scale, multi-national research projects could further amplify his contributions and align with broader global research priorities.

Professional Experience

Passage Bio, Philadelphia, PA
Executive Director, Biomarkers and Precision Medicine
2021-Present
Senior Director, Head of Biomarkers and Precision Medicine
2020-2021

Built and led a high-performing team responsible for driving clinical biomarker, PK/biodistribution, immunogenicity studies, and supporting clinical operations.

Developed and implemented biomarker, PK, and immunogenicity strategies to inform decision-making for neurodegenerative disease portfolios.

Led biomarker and precision medicine support for IND/CTA submissions and global regulatory interactions.

Oversaw partnerships with external CROs and laboratories, and collaborated with Clinical Study Teams on biomarker inclusion in clinical portfolios.

Regeneron, Tarrytown, NY
Associate Director, Precision Medicine, Early Clinical Development & Experimental Sciences
2016-2020

Designed and implemented biomarker strategies to support dose selection and efficacy readings for complement-mediated rare diseases.

Provided strategic leadership for discovery and early cardiovascular programs, influencing biomarker-driven decisions on target validation, disease indication selection, and patient stratification.

Led multiple biomarker-focused natural history studies with academic and clinical centers.

Bristol Myers Squibb, Princeton, NJ
Senior Research Investigator II, R&D/PD/ABD/BAS-Biologics
2012-2016

Supported biomarker bioanalytical strategy implementation for immuno-oncology, immunology, and cardiovascular diseases.

Supervised biomarker method development and validation by internal staff and CROs.

Provided strategic and technical input on biomarker bioanalytical plans, resources, and timelines for FIH and PoC studies.

Merck & Co., Inc., Rahway, NJ
Senior Research Scientist, Cardiovascular Franchise Atherosclerosis Group
2007-2011

Led the development of a 2nd generation fully human monoclonal antibody for PCSK9.

Established ELISA-based pharmacodynamics and target engagement biomarker assays.

University of Texas Southwestern Medical Center, Dallas, TX
Research Assistant Professor, Internal Medicine Department, Cardiology
2001-2007
Research Scientist, Department of Pharmacology & Alliance for Cellular Signaling
2001-2007

Conducted research on cardiac hypertrophy, heart failure, and aging, focusing on Akt and FOXO transcriptional factors.

Education and Training

Persuasive Leadership Development: Wharton Business School, University of Pennsylvania

Postdoctoral Training: Yale University, under Professors Gary Rudnick and Eric Nestler

Ph.D. in Neuroscience: University of California, Irvine, under Professor Ricardo Miledi

M.S. in Pharmacology: Institute of Basic Medical Sciences, Beijing, China

B.S. in Biochemistry: Anhui University, Hefei, China

Professional Honors

Passage Bio High Impact Award (2021)

Regeneron High Impact Award and Multiple STAR Awards (2016-2020)

AAPS Excellence in Ligand Binding Assays Award (2015)

BMS R&D ROC Award and Multiple STAR Awards (2014)

Merck Award of Excellence (2007, 2008, 2009)

Professional Affiliations

American Association of Pharmaceutical Scientists (AAPS):

Founding Member and Chair of the Biomarkers and Translational Medicine Community

Founding Member and Chair of the Gene and Cell Therapeutic Products Community

Sino-American Pharmaceutical Professionals Association (SAPA):

Director for Public Outreach and Executive Committee Member

Publications

Yang, J., Mapelli, C., Wang, Z., et al. (2022). An Optimized Agonist Peptide of Protease-activated Receptor 4 and its Use in a Platelet Aggregation Assay to Monitor the Pharmacodynamic Effects of PAR4 Antagonists. Platelets. DOI: 10.1080/09537104.2022.2053091

Hays, A., Amaravadi, L., Fernandez-Metzler, C., et al. (2022). Is Incurred Sample Reanalysis (ISR) applicable in Biomarker Assays? AAPS J, 24:65. DOI: 10.1208/s12248-022-00708-y

Ni, Y.G., King, L., Fernández-Metzler, C. (2022). Recent Progress in Biomarker Bioanalysis and Target Engagement in Bioanalytical Aspects in Biological Therapeutics. ISBN: 9781119523215. Edited by Xu, X. & Xu, W.

Conclusion:

Dr. Yan G. Ni, PhD, is an outstanding candidate for the “Best Researcher Award” based on his extensive contributions to drug development, biomarker research, and precision medicine. His leadership, scientific productivity, and recognition by peers make him a strong contender for the award. However, expanding his research impact into broader and more emerging fields could further strengthen his profile for this prestigious recognition.